Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.39 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.39 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18215382 | 1.00 | TSHR (0.54) | TSHRSMN1; SMN2KCNH2HRH3SLC18A3 | |
| SCHEMBL18388973 | 1.00 | TSHR (0.54) | TSHRSMN1; SMN2KCNH2HRH3SLC18A3 | |
| SCHEMBL1266842 | 0.98 | TSHR (0.52) | TSHRSMN1; SMN2KCNH2HRH3SLC18A3 | |
| SCHEMBL17414393 | 0.93 | TSHR (0.56) | TSHRSMN1; SMN2KCNH2HRH3SLC6A2 | |
| SCHEMBL28414 | 0.93 | TSHR (0.56) | TSHRSMN1; SMN2KCNH2HRH3SLC6A2 | |
| Water SCHEMBL7156214 | 0.91 | TSHR (0.54) | TSHRSMN1; SMN2KCNH2HRH3SLC6A2 | |
| SCHEMBL28318493 | 0.91 | TSHR (0.54) | TSHRSMN1; SMN2KCNH2HRH3SLC6A2 | |
| SCHEMBL23483031 | 0.88 | PRKAG1 (0.44) | TSHRKCNH2HRH3PRKAG1PRKAA1 | |
| SCHEMBL1195857 | 0.86 | TSHR (0.64) | TSHRSMN1; SMN2SLC18A3SLC6A2SLC6A4 | |
| Trimethylammonium SCHEMBL14720864 | 0.86 | TSHR (0.48) | TSHRSMN1; SMN2KCNH2HRH3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063326-A | Method for promoting nickel catalysis to synthesize arylamine compound by red light | 陕西师范大学 | 2024-05-24 | — | — | CN | claimed |
| US-20240122941-A1 | THERAPY BASED ON SYNTHETIC LETHALITY IN SWI/SNF COMPLEX-DYSFUNCTION CANCER | NATIONAL CANCER CENTER (JP) | 2024-04-18 | — | — | US | claimed |
| CN-116568786-A | Synergistic perfuming composition | 弗门尼舍有限公司 | 2023-08-08 | — | — | CN | claimed |
| CN-116528818-A | Synergistic perfuming composition | 弗门尼舍有限公司 | 2023-08-01 | — | — | CN | claimed |
| US-11535647-B2 | Peptide purification method using sulfonate compound | NAGASE & CO., LTD. (JP) | 2022-12-27 | — | — | US | claimed |
| CN-114752053-A | Polycarbonate resin, method for producing same, and optical lens | 三菱瓦斯化学株式会社 | 2022-07-15 | — | — | CN | claimed |
| CN-114716658-A | Polycarbonate resin, method for producing same, and optical lens | 三菱瓦斯化学株式会社 | 2022-07-08 | — | — | CN | claimed |
| US-20220144888-A1 | PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND | NAGASE & CO., LTD. (JP) | 2022-05-12 | — | — | US | claimed |
| CN-111440132-B | Novel method for preparing oxygen heterocyclic compound by ionic liquid catalysis | 中国科学院化学研究所 | 2022-02-01 | — | — | CN | claimed |
| WO-2022017444-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2022-01-27 | — | — | WO | claimed |
| WO-2006127228-A1 | METHOD OF FORMING NANOCOMPOSITE MATERIALS | UNIVERSITY OF DAYTON (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060079623-A1 | Method of forming nanocomposite materials | AIR FORCE, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE | 2006-04-13 | — | — | US | claimed |
| WO-2006003096-A1 | CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2006-01-12 | — | — | WO | claimed |
| EP-1389194-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-18 | — | — | EP | claimed |
| US-20030095958-A1 | Inhibitors of bace | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | claimed |
| CN-1411522-A | Enzymatic process for dyeing with vat and sulphur dyes | NOVOZYMES BIOTECH INC (US) | 2003-04-16 | — | — | CN | claimed |
| US-6503926-B2 | Nitrogen heterocycle compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-07 | — | — | US | claimed |
| WO-2002088101-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | claimed |
| US-6288083-B1 | ADMINISTERING COMOUNDS SUCH AS 4-(4-CHLOROPHENYL)-1-(4-(3-METHOXYPHENYL)-4-(3-PYRIDINYL)-3 -BUTENYL)PIPERIDIN-4-OL TO TREAT DISEASES ASSOCIATED WITH ABERRANT LEUKOCYTE RECRUITMENT AND/OR ACTIVATION | MILLENNIUM PHARMACEUTICALS, INC. | 2001-09-11 | — | — | US | claimed |
| WO-1992011006-A1 | THERAPEUTICAL AGENT AGAINST VIRAL DISEASES | DEUTSCHES PRIMATENZENTRUM GMBH (DE) | 1992-07-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030095958-A1 | Inhibitors of bace | BACE2, BACE1, APP | TSHR 4868/4885SMN1; SMN2 1876/4885KCNH2 4359/4885 |
| US-20220144888-A1 | PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND | VIP, IAPP, RPS27A | TSHR 1129/4885SMN1; SMN2 1752/4885KCNH2 4255/4885 |
| US-11535647-B2 | Peptide purification method using sulfonate compound | VIP, IAPP, RPS27A | TSHR 1129/4885SMN1; SMN2 1752/4885KCNH2 4255/4885 |
| US-20240122941-A1 | THERAPY BASED ON SYNTHETIC LETHALITY IN SWI/SNF COMPLEX-DYSFUNCTION CANCER | SMARCC1, SMARCA4, SMARCC2 | TSHR 3169/4885SMN1; SMN2 914/4885KCNH2 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.